# Annexon, Inc. (ANNX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ANNX
## Company Profile
- Ticker: ANNX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 5.34 USD
- Market cap: 861811749.88 USD
- Last updated: 2026-08-11
## Business Overview
### Classical Complement Inhibition
Annexon develops therapies that inhibit the classical complement pathway, which can drive harmful inflammation and tissue damage in neurologic, ophthalmic, and autoimmune diseases.
### Tanruprubart
Tanruprubart is an antibody therapy for Guillain-Barré syndrome. Its European marketing application is under review, and Annexon is preparing a U.S. biologics license application supported by clinical and real-world evidence.
### Vonaprument
Vonaprument is a complement inhibitor in the pivotal Phase 3 ARCHER II study for geographic atrophy, an advanced form of dry age-related macular degeneration. The program aims to preserve vision by blocking upstream complement activation.
### ANX1502
ANX1502 is an oral C1s inhibitor intended to extend classical-complement modulation into chronic autoimmune diseases. A proof-of-concept study is evaluating the candidate in cold agglutinin disease.
## Why The Stock Is Moving

The latest monitored company update is “Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Proof-of-concept update for ANX1502 in cold agglutinin disease in fall 2026.
- Month 15 primary-endpoint results from the Phase 3 ARCHER II study of vonaprument in the fourth quarter of 2026.
- Submission of a BLA for tanruprubart in Guillain-Barré syndrome in the fourth quarter of 2026.
- Completion of ARCHER II, including the Month 24 primary endpoint, in the third quarter of 2027.

## Recent News
- 2026-08-12 10:05 EST — [Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones](https://biopharmsignal.com/news/ANNX/annexon-reports-second-quarter-2026-financial-results-business-updates-and-key-a-97b91604) — Source: Annexon, Inc.
- 2026-08-12 10:00 EST — [Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study](https://biopharmsignal.com/news/ANNX/annexon-expands-vonaprument-phase-3-program-in-geographic-atrophy-with-addition--5ed8b4ce) — Source: Annexon, Inc.
- 2026-08-10 20:05 EST — [Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors](https://biopharmsignal.com/news/ANNX/annexon-appoints-renowned-retinal-surgeon-and-biotechnology-entrepreneur-mark-s--5fb317e6) — Source: Annexon, Inc.
- 2026-08-06 12:00 EST — [Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week](https://biopharmsignal.com/news/ANNX/annexon-reports-first-u-s-and-european-patient-cohort-of-gbs-forward-study-demon-55ea85ca) — Source: Annexon, Inc.
- 2026-07-30 20:01 EST — [Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance](https://biopharmsignal.com/news/ANNX/annexon-secures-strategic-credit-facility-for-up-to-200-million-from-oxford-fina-e092eb12) — Source: Annexon, Inc.